Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28202799 | 0.82 | ABHD6 (0.44) | ABHD6UCHL1DPP8DPP9PRMT5 | |
| SCHEMBL4890883 | 0.82 | TMEM97 (0.53) | PTGDR2TMEM97SIGMAR1KMT2A | |
| SCHEMBL4781391 | 0.81 | ABHD6 (0.43) | ABHD6UCHL1DPP8DPP9PRMT5 | |
| SCHEMBL8276042 | 0.80 | PRMT5 (0.53) | ABHD6DPP8DPP9PRMT5WDR77 | |
| SCHEMBL7533300 | 0.76 | DPP8 (0.52) | DPP8DPP9PRMT5WDR77EPHX2 | |
| SCHEMBL28263416 | 0.74 | TSHR (0.45) | DPP8DPP9PRMT5WDR77EPHX2 | |
| SCHEMBL16523597 | 0.72 | ESR2 (0.48) | PRMT5WDR77EPHX2TMEM97SIGMAR1 | |
| SCHEMBL13327274 | 0.72 | POLB (0.52) | EPHX2KMT2AFABP7FABP5 | |
| SCHEMBL22397770 | 0.72 | POLB (0.52) | EPHX2KMT2AFABP7FABP5 | |
| SCHEMBL1128835 | 0.71 | POLB (0.47) | EPHX2KMT2AFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | ABHD6 4438/4885UCHL1 4407/4885DPP8 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.